Immatics Reports Q3 Financial Results and Cash Runway Extension
Immatics (NASDAQ: IMTX) reported its third-quarter financial results, showing a net loss of $49.4 million, a slight improvement from the $50.6 million loss recorded in the previous period. The company maintains a strong liquidity position with total cash, equivalents, and investments totaling $313.8 million as of September 30, 2026. Based on its current operating plan, management expects these financial resources to provide an operational runway extending into 2029. Market analysts are closely watching the development of Anzu-Cel, citing potential catalysts in the first half of 2027 and possible label expansion for uveal melanoma as key drivers for future value.
Tickers: $IMTX
Topics: biotechnology cash runway net loss quarterly earnings
Read the full article at Seeking Alpha
Part of the story Immatics Reports Q3 Financial Results and Cash Runway Extension (2 articles)